Melanoma Quiz

Quiz

Quiz: Cost of Ipilimumab vs High-Dose Interferon for Melanoma

11/11/2021

True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.

True or False: Although,...

11/11/2021

Journal of Clinical Pathways

Quiz

Quiz: Ipilimumab Among Patients With Metastatic Melanoma

10/29/2021

True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.

True or False: Real-world...

10/29/2021

Journal of Clinical Pathways

Quiz

Quiz: Dermoscopic Structures and Patterns in Melanoma Detection

10/12/2021

True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.

True or False: There is...

10/12/2021

Journal of Clinical Pathways

Quiz

Quiz: Pembrolizumab for the Treatment of BRAF-Mutant Stage III Melanoma

09/07/2021

True or False: For the treatment of BRAF-mutant stage III melanoma, pembrolizumab is most cost-effective at a conventional willingness-to-pay threshold.

True or False: For the treatment...

09/07/2021

Journal of Clinical Pathways

Quiz

Quiz: Dabrafenib–Trametinib for Treating Melanoma

08/23/2021

True or False: Dabrafenib–trametinib offers incremental quality-adjusted life years in patients with BRAF-mutant stage III melanoma, but it is not considered cost-effective.

True or False:...

08/23/2021

Journal of Clinical Pathways

Quiz

Quiz: First-Year Costs Among Patients With Melanoma

08/18/2021

Journal of Clinical Pathways

Quiz

Quiz: Ipilimumab for the Treatment of Metastatic Melanoma

07/29/2021

True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.

True or False: Across first-line...

07/29/2021

Journal of Clinical Pathways

Quiz

Quiz: Adverse Event Costs Among Patients With Metastatic Melanoma

07/20/2021

True or False: Costs associated with adverse events among patients with metastatic melanoma are small, encompassing only 3% of total costs.

True or False: Costs associated...

07/20/2021

Journal of Clinical Pathways

Quiz

Quiz: Immune Checkpoint Inhibitors (ICIs) in Cutaneous Metastatic Melanoma

03/10/2021

Journal of Clinical Pathways

Quiz

Quiz: Medicare Fee-for-Service Pricing Impact on Skin Cancer Procedures

01/05/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Melanoma Quiz

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products